share_log

8-K: Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

8-K: Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

8-K:Cingulate公佈2024年第二季度財務業績,並提供已實現的重大里程碑的最新發展情況
美股SEC公告 ·  08/13 20:02

牛牛AI助理已提取核心訊息

On August 13, 2024, Cingulate Inc., a biopharmaceutical company, announced its financial results for the second quarter ended June 30, 2024, and provided updates on its clinical and business developments. The company reported significant progress with its lead product candidate, CTx-1301, for the treatment of ADHD, including FDA clearance to file for marketing approval and the completion of registration batches, which are essential for a New Drug Application (NDA) submission targeted for the first half of 2025. Cingulate also completed a payer study to assess the market potential for CTx-1301 and raised $1.6 million through a warrant inducement. Additionally, the company executed a one-for-twelve reverse stock split to comply with Nasdaq's Minimum Bid Price requirement. As of June 30, 2024, Cingulate had cash and cash equivalents of $0.4 million and total liabilities of $1.9 million, a decrease from the previous year. The company's net loss for the quarter was $3.2 million, a decrease from the $6.6 million loss reported for the same period in 2023, primarily due to reduced R&D and G&A expenses.
On August 13, 2024, Cingulate Inc., a biopharmaceutical company, announced its financial results for the second quarter ended June 30, 2024, and provided updates on its clinical and business developments. The company reported significant progress with its lead product candidate, CTx-1301, for the treatment of ADHD, including FDA clearance to file for marketing approval and the completion of registration batches, which are essential for a New Drug Application (NDA) submission targeted for the first half of 2025. Cingulate also completed a payer study to assess the market potential for CTx-1301 and raised $1.6 million through a warrant inducement. Additionally, the company executed a one-for-twelve reverse stock split to comply with Nasdaq's Minimum Bid Price requirement. As of June 30, 2024, Cingulate had cash and cash equivalents of $0.4 million and total liabilities of $1.9 million, a decrease from the previous year. The company's net loss for the quarter was $3.2 million, a decrease from the $6.6 million loss reported for the same period in 2023, primarily due to reduced R&D and G&A expenses.
2024年8月13日,生物醫藥公司Cingulate公司宣佈了截至2024年6月30日第二季度的財務成果,並針對其臨床和業務發展提供了更新。該公司的主力產品候選CTx-1301在治療注意力不足過動症方面取得了重大進展,包括獲得FDA准許提交營銷批准的申請和完成註冊批次,這對於2025年上半年的新藥申請(NDA)至關重要。Cingulate還完成了一項支付方研究,以評估CTx-1301的市場潛力,並通過權證誘因融資籌集了160萬美元。此外,該公司實施了一項1比12的股票拆分,以符合納斯達克的最低買入價格要求。截至2024年6月30日,Cingulate擁有40萬美元的現金及現金等價物和190萬美元的總負債,相較於去年有所減少。該公司本季度的淨虧損爲320萬美元,相較於2023年同期的660萬美元的虧損有所減少,主要由於研發和一般管理費用的減少。
2024年8月13日,生物醫藥公司Cingulate公司宣佈了截至2024年6月30日第二季度的財務成果,並針對其臨床和業務發展提供了更新。該公司的主力產品候選CTx-1301在治療注意力不足過動症方面取得了重大進展,包括獲得FDA准許提交營銷批准的申請和完成註冊批次,這對於2025年上半年的新藥申請(NDA)至關重要。Cingulate還完成了一項支付方研究,以評估CTx-1301的市場潛力,並通過權證誘因融資籌集了160萬美元。此外,該公司實施了一項1比12的股票拆分,以符合納斯達克的最低買入價格要求。截至2024年6月30日,Cingulate擁有40萬美元的現金及現金等價物和190萬美元的總負債,相較於去年有所減少。該公司本季度的淨虧損爲320萬美元,相較於2023年同期的660萬美元的虧損有所減少,主要由於研發和一般管理費用的減少。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。